ESR1 rs2046210 — When Estrogen Receptor Expression Is Turned Up
Estrogen receptor alpha (ERα), encoded by ESR1, is the master mediator of estrogen's effects on
reproductive tissue. It sits in the nucleus of endometrial, breast, and uterine cells, waiting for
estrogen to arrive — and when it does, it binds estrogen and turns on hundreds of downstream genes
controlling cell growth, differentiation, and inflammation. Getting the amount of ERα right matters
enormously: too much, and tissues become hypersensitive to estrogen, proliferating when they shouldn't.
rs2046210 sits in the promoter region | A promoter is a DNA region immediately upstream of a gene
where transcription machinery binds to start copying the gene into RNA
approximately 29 kilobases upstream of the ESR1 transcription start site, between the
C6orf97/CCDC170 gene and ESR1 itself. The A allele alters the chromatin environment at this
locus in a way that increases baseline ESR1 transcription — meaning cells that carry the A allele
simply produce more estrogen receptor protein, making the entire estrogen-signaling axis more reactive.
The Mechanism
The variant was discovered in a
genome-wide association study of Chinese women | Zheng et al. Nature Genetics, 2009
and confirmed as a regulatory locus by eQTL (expression quantitative trait locus) analyses showing
that risk-allele carriers have statistically higher expression of ESR1 in adjacent normal breast tissue
(P = 0.04) and in the eutopic endometrium of women with endometriosis.
Functional studies | Sun et al. Carcinogenesis, 2016
also implicate the nearby AKAP12 gene, whose expression correlates with rs2046210 genotype in the
same tissue samples (P = 0.02). The net effect is a constitutively elevated estrogen-sensing state in
sensitive reproductive tissues, which predisposes to estrogen-driven proliferative conditions.
For endometriosis specifically, the mechanism is particularly direct: elevated ERα in ectopic
endometrial-like lesions amplifies their response to circulating estrogen, promoting growth, survival,
and inflammatory signaling in lesions implanted on peritoneal surfaces, ovaries, and pelvic ligaments.
A 2024 Austrian case-control study | Proestling et al. Biomedicines, 2024
found significantly increased ESR1 expression in eutopic endometrium of women with endometriosis
who carried the GA genotype — confirming the mechanistic link between the rs2046210 risk allele and
enhanced estrogen receptor signaling in affected tissue.
The Evidence
The breast cancer data is the most statistically robust due to sample size. The discovery GWAS by
Zheng et al. (2009) | Nature Genetics; 1,505 cases and 1,522 controls in Chinese women with two
independent replication cohorts
identified rs2046210 as genome-wide significant (P = 2.0 × 10⁻¹⁵). The odds ratios were
1.36 (95% CI 1.24–1.49) for heterozygotes (AG) and 1.59 (95% CI 1.40–1.82) for homozygotes (AA)
compared to GG. These numbers were confirmed across >31,000 women in Chinese, Japanese, and European
populations by
Cai et al. (2011) | Cancer Research,
and further consolidated in a
meta-analysis of 235,003 subjects (13 studies) | Wu et al. PLoS One, 2013
showing per-allele OR 1.13 (95% CI 1.10–1.17). A larger meta-analysis of
121,494 cases and 119,295 controls (14 studies) | Yang et al. Breast Cancer Research and Treatment, 2013
replicated the A allele association with OR 1.16 (95% CI 1.11–1.21).
The endometriosis evidence is more recent and from smaller studies. The 2024 Proestling et al. paper
is the first to directly link rs2046210 to endometriosis risk and elevated ESR1 expression in
endometrial tissue, with the GA genotype driving the association particularly in younger, leaner,
and infertile women — the classic endometriosis clinical profile. The endometrial cancer association,
shown in a Chinese population-based study (OR 1.28 in postmenopausal women), provides corroborating
evidence that the locus broadly sensitizes estrogen-responsive gynecological tissue.
The risk conferred by a single common variant of this effect size is moderate on an individual level —
an OR of 1.36 for heterozygotes means roughly 36% higher relative risk compared to GG, which, against
a population endometriosis prevalence of ~10%, translates to an absolute shift of a few percentage
points. It is more meaningful as a biological signal — pointing to estrogen receptor upregulation as a
mechanism — than as a standalone clinical predictor.
Practical Actions
The clinical implication of elevated ESR1 expression is heightened sensitivity to estrogen. Interventions
that modulate estrogen bioavailability — either by reducing exposure or supporting efficient estrogen
metabolism — are especially relevant for risk-allele carriers.
For endometriosis specifically, the combination of elevated estrogen sensitivity and the high diagnostic
delay (4–11 years on average) argues for proactive symptom recognition and early specialist evaluation.
Risk-allele carriers who have gynecological symptoms consistent with endometriosis should request
specialist evaluation rather than accept normalization of pain.
Dietary indole-3-carbinol (I3C) from cruciferous vegetables promotes 2-hydroxylation of estradiol
via CYP1A1/CYP1A2, shifting metabolism toward the less proliferative 2-OH pathway and away from
16-α-OH estrone, which has been shown to reduce estrogenic proliferative signaling in endometrial
and breast tissue. This is particularly relevant when ESR1 expression is constitutively elevated.
Interactions
rs12700667 (7p15.2 / HOXA10-HOXA11 locus): The 7p15.2 locus is one of the strongest replicated
endometriosis GWAS signals. Carrying risk alleles at both rs2046210 (increased ESR1 expression) and
rs12700667 (altered HOX gene regulation affecting endometrial development) represents two mechanistically
distinct pathways converging on endometriosis susceptibility — one increasing estrogen sensitivity, the
other impairing normal endometrial patterning. Women carrying risk alleles at both loci may represent
a subgroup with meaningfully higher cumulative endometriosis risk. Combined recommendation: earlier
gynecological evaluation, proactive fertility workup, and lower threshold for diagnostic laparoscopy.
Evidence level: moderate (both loci well-replicated; interaction testing not formally published).
rs9383590 (ESR1 coding region): rs9383590 is a coding-region ESR1 variant studied alongside
rs2046210 in breast cancer. Both showed independent effects on breast cancer age at onset in the
Miedl et al. (2023) study, with minor homozygotes presenting years earlier than common homozygotes
in ER-positive and luminal cancers. Compound effects of rs2046210 (upstream regulatory) and rs9383590
(coding/functional) on ESR1 activity have not been formally tested in endometriosis.
Alla genotyper
No copies of the ESR1 upstream risk allele
You carry two copies of the G allele at rs2046210, the common protective genotype. About 43% of people of European ancestry share this genotype. You do not carry the A allele that is associated with elevated ESR1 expression and increased risk of estrogen-sensitive conditions including endometriosis, endometrial cancer, and breast cancer at this locus. This does not eliminate your risk of these conditions — they are influenced by many genetic and lifestyle factors — but this particular estrogen receptor regulatory signal is not elevated for you.
One copy of the ESR1 upstream risk allele — elevated estrogen receptor expression
You carry one copy of the A risk allele at rs2046210. The odds ratio for endometriosis in heterozygous carriers is significantly elevated, particularly in younger, leaner, and infertile women. For breast cancer, large meta-analyses consistently report an OR of approximately 1.30–1.36 for heterozygotes compared to GG in Asian populations, and approximately 1.07–1.14 in European populations. About 45% of people of European ancestry are heterozygous at this locus. The A allele increases baseline expression of estrogen receptor alpha (ERα) in reproductive tissue, making cells more sensitive to circulating estrogen. This elevated estrogen sensitivity is especially relevant for estrogen-dependent conditions such as endometriosis and endometrial cancer.
Two copies of the ESR1 upstream risk allele — highest estrogen receptor expression at this locus
You carry two copies of the A risk allele at rs2046210. Under the additive model confirmed for this locus, AA homozygotes carry approximately twice the additional risk of AG heterozygotes. The original discovery GWAS reported an odds ratio of 1.59 (95% CI 1.40–1.82) for AA versus GG for breast cancer. The 2024 endometriosis study identified the AA genotype as a risk factor specifically for endometriosis progression in women with mild disease. About 12% of people of European ancestry are homozygous for the A allele. Two A alleles produce the highest baseline level of estrogen receptor alpha expression at this locus, creating the greatest estrogen sensitivity in reproductive and breast tissue. The biological consequence is a constitutively primed estrogenic signaling state across multiple target tissues simultaneously.